ID   SPG7_HUMAN              Reviewed;         795 AA.
AC   Q9UQ90; O75756; Q2TB70; Q58F00; Q96IB0;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   28-JAN-2026, entry version 229.
DE   RecName: Full=Mitochondrial inner membrane m-AAA protease component paraplegin {ECO:0000305};
DE            EC=3.4.24.- {ECO:0000269|PubMed:11549317, ECO:0000269|PubMed:28396416, ECO:0000269|PubMed:31097542};
DE            EC=3.6.-.- {ECO:0000250|UniProtKB:Q9Y4W6};
DE   AltName: Full=Cell matrix adhesion regulator {ECO:0000312|HGNC:HGNC:11237};
DE   AltName: Full=Paraplegin {ECO:0000303|PubMed:9635427};
DE   AltName: Full=Spastic paraplegia 7 protein {ECO:0000312|HGNC:HGNC:11237};
DE   Flags: Precursor;
GN   Name=SPG7 {ECO:0000312|HGNC:HGNC:11237};
GN   Synonyms=CAR, CMAR {ECO:0000312|HGNC:HGNC:11237}, PGN;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, AND
RP   INVOLVEMENT IN SPG7.
RX   PubMed=9635427; DOI=10.1016/s0092-8674(00)81203-9;
RA   Casari G., De Fusco M., Ciarmatori S., Zeviani M., Mora M., Fernandez P.,
RA   De Michele G., Filla A., Cocozza S., Marconi R., Duerr A., Fontaine B.,
RA   Ballabio A.;
RT   "Spastic paraplegia and OXPHOS impairment caused by mutations in
RT   paraplegin, a nuclear-encoded mitochondrial metalloprotease.";
RL   Cell 93:973-983(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=10480368; DOI=10.1007/s004399900087;
RA   Settasatian C., Whitmore S.A., Crawford J., Bilton R.L.,
RA   Cleton-Jansen A.-M., Sutherland G.R., Callen D.F.;
RT   "Genomic structure and expression analysis of the spastic paraplegia gene,
RT   SPG7.";
RL   Hum. Genet. 105:139-144(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Duodenum, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION.
RX   PubMed=11549317; DOI=10.1006/geno.2001.6560;
RA   Kremmidiotis G., Gardner A.E., Settasatian C., Savoia A., Sutherland G.R.,
RA   Callen D.F.;
RT   "Molecular and functional analyses of the human and mouse genes encoding
RT   AFG3L1, a mitochondrial metalloprotease homologous to the human spastic
RT   paraplegia protein.";
RL   Genomics 76:58-65(2001).
RN   [5]
RP   INTERACTION WITH AFG3L2.
RX   PubMed=14623864; DOI=10.1083/jcb.200304112;
RA   Atorino L., Silvestri L., Koppen M., Cassina L., Ballabio A., Marconi R.,
RA   Langer T., Casari G.;
RT   "Loss of m-AAA protease in mitochondria causes complex I deficiency and
RT   increased sensitivity to oxidative stress in hereditary spastic
RT   paraplegia.";
RL   J. Cell Biol. 163:777-787(2003).
RN   [6]
RP   INVOLVEMENT IN OSTEOGENESIS IMPERFECTA.
RX   PubMed=20579626; DOI=10.1016/j.ajhg.2010.05.016;
RA   Lapunzina P., Aglan M., Temtamy S., Caparros-Martin J.A., Valencia M.,
RA   Leton R., Martinez-Glez V., Elhossini R., Amr K., Vilaboa N.,
RA   Ruiz-Perez V.L.;
RT   "Identification of a frameshift mutation in Osterix in a patient with
RT   recessive osteogenesis imperfecta.";
RL   Am. J. Hum. Genet. 87:110-114(2010).
RN   [7]
RP   FUNCTION, IDENTIFICATION IN THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE
RP   COMPLEX, INTERACTION WITH AFG3L2; PPIF AND VDAC1, AND MUTAGENESIS OF
RP   HIS-574; GLU-575 AND GLY-577.
RX   PubMed=26387735; DOI=10.1016/j.molcel.2015.08.009;
RA   Shanmughapriya S., Rajan S., Hoffman N.E., Higgins A.M., Tomar D.,
RA   Nemani N., Hines K.J., Smith D.J., Eguchi A., Vallem S., Shaikh F.,
RA   Cheung M., Leonard N.J., Stolakis R.S., Wolfers M.P., Ibetti J.,
RA   Chuprun J.K., Jog N.R., Houser S.R., Koch W.J., Elrod J.W., Madesh M.;
RT   "SPG7 is an essential and conserved component of the mitochondrial
RT   permeability transition pore.";
RL   Mol. Cell 60:47-62(2015).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [9]
RP   INTERACTION WITH MAIP1.
RX   PubMed=27499296; DOI=10.1016/j.molcel.2016.06.033;
RA   Floyd B.J., Wilkerson E.M., Veling M.T., Minogue C.E., Xia C., Beebe E.T.,
RA   Wrobel R.L., Cho H., Kremer L.S., Alston C.L., Gromek K.A., Dolan B.K.,
RA   Ulbrich A., Stefely J.A., Bohl S.L., Werner K.M., Jochem A.,
RA   Westphall M.S., Rensvold J.W., Taylor R.W., Prokisch H., Kim J.J.,
RA   Coon J.J., Pagliarini D.J.;
RT   "Mitochondrial protein interaction mapping identifies regulators of
RT   respiratory chain function.";
RL   Mol. Cell 63:621-632(2016).
RN   [10]
RP   FUNCTION, AND IDENTIFICATION IN THE M-AAA PROTEASE COMPLEX.
RX   PubMed=28396416; DOI=10.1073/pnas.1702938114;
RA   Tsai C.W., Wu Y., Pao P.C., Phillips C.B., Williams C., Miller C.,
RA   Ranaghan M., Tsai M.F.;
RT   "Proteolytic control of the mitochondrial calcium uniporter complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:4388-4393(2017).
RN   [11]
RP   FUNCTION, AND MUTAGENESIS OF 574-HIS--GLY-577.
RX   PubMed=31097542; DOI=10.1074/jbc.ra118.006443;
RA   Hurst S., Baggett A., Csordas G., Sheu S.S.;
RT   "SPG7 targets the m-AAA protease complex to process MCU for uniporter
RT   assembly, Ca2+ influx, and regulation of mitochondrial permeability
RT   transition pore opening.";
RL   J. Biol. Chem. 294:10807-10818(2019).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.22 ANGSTROMS) OF 305-565 IN COMPLEX WITH ATP
RP   ANALOG ADP.
RX   PubMed=19841671; DOI=10.1371/journal.pone.0006975;
RA   Karlberg T., van den Berg S., Hammarstrom M., Sagemark J., Johansson I.,
RA   Holmberg-Schiavone L., Schuler H.;
RT   "Crystal structure of the ATPase domain of the human AAA+ protein
RT   paraplegin/SPG7.";
RL   PLoS ONE 4:E6975-E6975(2009).
RN   [13]
RP   VARIANTS SPG7 VAL-510 AND VAL-581 DEL, AND VARIANTS THR-2; GLN-82 DEL;
RP   PRO-284; HIS-294; GLN-486; ALA-503; LEU-545; THR-603; LEU-635; THR-645;
RP   HIS-650; GLN-688 AND ASP-730.
RX   PubMed=16534102; DOI=10.1212/01.wnl.0000201185.91110.15;
RA   Elleuch N., Depienne C., Benomar A., Hernandez A.M., Ferrer X.,
RA   Fontaine B., Grid D., Tallaksen C.M.E., Zemmouri R., Stevanin G., Durr A.,
RA   Brice A.;
RT   "Mutation analysis of the paraplegin gene (SPG7) in patients with
RT   hereditary spastic paraplegia.";
RL   Neurology 66:654-659(2006).
RN   [14]
RP   VARIANT SPG7 THR-692.
RX   PubMed=17646629; DOI=10.1212/01.wnl.0000266667.91074.fe;
RA   Warnecke T., Duning T., Schwan A., Lohmann H., Epplen J.T., Young P.;
RT   "A novel form of autosomal recessive hereditary spastic paraplegia caused
RT   by a new SPG7 mutation.";
RL   Neurology 69:368-375(2007).
RN   [15]
RP   VARIANTS SPG7 SER-349; VAL-510 AND CYS-583, VARIANTS ALA-503 AND GLN-688,
RP   CHARACTERIZATION OF VARIANTS SPG7 SER-349; VAL-510 AND CYS-583, AND
RP   CHARACTERIZATION OF VARIANTS ALA-503 AND GLN-688.
RX   PubMed=20186691; DOI=10.1002/humu.21226;
RA   Bonn F., Pantakani K., Shoukier M., Langer T., Mannan A.U.;
RT   "Functional evaluation of paraplegin mutations by a yeast complementation
RT   assay.";
RL   Hum. Mutat. 31:617-621(2010).
RN   [16]
RP   VARIANT SPG7 VAL-510.
RX   PubMed=27217339; DOI=10.1093/brain/aww111;
RA   Kara E., Tucci A., Manzoni C., Lynch D.S., Elpidorou M., Bettencourt C.,
RA   Chelban V., Manole A., Hamed S.A., Haridy N.A., Federoff M., Preza E.,
RA   Hughes D., Pittman A., Jaunmuktane Z., Brandner S., Xiromerisiou G.,
RA   Wiethoff S., Schottlaender L., Proukakis C., Morris H., Warner T.,
RA   Bhatia K.P., Korlipara L.V., Singleton A.B., Hardy J., Wood N.W.,
RA   Lewis P.A., Houlden H.;
RT   "Genetic and phenotypic characterization of complex hereditary spastic
RT   paraplegia.";
RL   Brain 139:1904-1918(2016).
CC   -!- FUNCTION: Catalytic component of the m-AAA protease, a protease that
CC       plays a key role in proteostasis of inner mitochondrial membrane
CC       proteins, and which is essential for axonal and neuron development
CC       (PubMed:11549317, PubMed:28396416, PubMed:31097542, PubMed:9635427).
CC       SPG7 possesses both ATPase and protease activities: the ATPase activity
CC       is required to unfold substrates, threading them into the internal
CC       proteolytic cavity for hydrolysis into small peptide fragments (By
CC       similarity). The m-AAA protease exerts a dual role in the mitochondrial
CC       inner membrane: it mediates the processing of specific regulatory
CC       proteins and ensures protein quality control by degrading misfolded
CC       polypeptides (By similarity). Mediates protein maturation of the
CC       mitochondrial ribosomal subunit MRPL32/bL32m by catalyzing the cleavage
CC       of the presequence of MRPL32/bL32m prior to assembly into the
CC       mitochondrial ribosome (By similarity). Acts as a regulator of calcium
CC       in neurons by mediating degradation of SMDT1/EMRE before its assembly
CC       with the uniporter complex, limiting the availability of SMDT1/EMRE for
CC       MCU assembly and promoting efficient assembly of gatekeeper subunits
CC       with MCU (PubMed:28396416, PubMed:31097542). Also regulates
CC       mitochondrial calcium by catalyzing degradation of MCU
CC       (PubMed:31097542). Plays a role in the formation and regulation of the
CC       mitochondrial permeability transition pore (mPTP) and its proteolytic
CC       activity is dispensable for this function (PubMed:26387735).
CC       {ECO:0000250|UniProtKB:Q3ULF4, ECO:0000250|UniProtKB:Q9Y4W6,
CC       ECO:0000269|PubMed:11549317, ECO:0000269|PubMed:26387735,
CC       ECO:0000269|PubMed:28396416, ECO:0000269|PubMed:31097542,
CC       ECO:0000269|PubMed:9635427}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000250|UniProtKB:Q9Y4W6};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:13066;
CC         Evidence={ECO:0000250|UniProtKB:Q9Y4W6};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000250|UniProtKB:Q9Y4W6};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250|UniProtKB:Q9Y4W6};
CC   -!- SUBUNIT: Forms heterooligomers with AFG3L2; the m-AAA protease is
CC       composed of heterohexamers of AFG3L2 and SPG7 (PubMed:14623864,
CC       PubMed:28396416). Component of the mitochondrial permeability
CC       transition pore complex (mPTPC), at least composed of SPG7, VDAC1 and
CC       PPIF (PubMed:26387735). Interacts with MAIP1 (PubMed:27499296).
CC       {ECO:0000269|PubMed:14623864, ECO:0000269|PubMed:26387735,
CC       ECO:0000269|PubMed:27499296, ECO:0000269|PubMed:28396416}.
CC   -!- INTERACTION:
CC       Q9UQ90; O95273: CCNDBP1; NbExp=3; IntAct=EBI-717201, EBI-748961;
CC       Q9UQ90; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-717201, EBI-3867333;
CC       Q9UQ90; P61978: HNRNPK; NbExp=6; IntAct=EBI-717201, EBI-304185;
CC       Q9UQ90; P61978-2: HNRNPK; NbExp=3; IntAct=EBI-717201, EBI-7060731;
CC       Q9UQ90; O75031: HSF2BP; NbExp=3; IntAct=EBI-717201, EBI-7116203;
CC       Q9UQ90; Q5VWX1: KHDRBS2; NbExp=3; IntAct=EBI-717201, EBI-742808;
CC       Q9UQ90; Q6A162: KRT40; NbExp=3; IntAct=EBI-717201, EBI-10171697;
CC       Q9UQ90; P60409: KRTAP10-7; NbExp=3; IntAct=EBI-717201, EBI-10172290;
CC       Q9UQ90; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-717201, EBI-10172052;
CC       Q9UQ90; Q9BRK4: LZTS2; NbExp=3; IntAct=EBI-717201, EBI-741037;
CC       Q9UQ90; Q99750: MDFI; NbExp=7; IntAct=EBI-717201, EBI-724076;
CC       Q9UQ90; Q5JR59: MTUS2; NbExp=4; IntAct=EBI-717201, EBI-742948;
CC       Q9UQ90; Q9Y6M9: NDUFB9; NbExp=2; IntAct=EBI-717201, EBI-713654;
CC       Q9UQ90; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-717201, EBI-945833;
CC       Q9UQ90; P0DPK4: NOTCH2NLC; NbExp=3; IntAct=EBI-717201, EBI-22310682;
CC       Q9UQ90; Q8ND90: PNMA1; NbExp=7; IntAct=EBI-717201, EBI-302345;
CC       Q9UQ90; P61289: PSME3; NbExp=3; IntAct=EBI-717201, EBI-355546;
CC       Q9UQ90; O43586: PSTPIP1; NbExp=3; IntAct=EBI-717201, EBI-1050964;
CC       Q9UQ90; Q93062: RBPMS; NbExp=3; IntAct=EBI-717201, EBI-740322;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane
CC       {ECO:0000269|PubMed:9635427}; Multi-pass membrane protein
CC       {ECO:0000255}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9UQ90-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9UQ90-2; Sequence=VSP_009192, VSP_009193;
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- PTM: Upon import into the mitochondrion, the N-terminal transit peptide
CC       is cleaved by the mitochondrial-processing peptidase (MPP) to generate
CC       an intermediate form which undergoes a second proteolytic cleavage
CC       mediated by proteases AFG3L2 removing an additional N-terminal fragment
CC       to generate the proteolytically active mature form.
CC       {ECO:0000250|UniProtKB:Q3ULF4}.
CC   -!- DISEASE: Spastic paraplegia 7, autosomal recessive (SPG7) [MIM:607259]:
CC       A form of spastic paraplegia, a neurodegenerative disorder
CC       characterized by a slow, gradual, progressive weakness and spasticity
CC       of the lower limbs. Rate of progression and the severity of symptoms
CC       are quite variable. Initial symptoms may include difficulty with
CC       balance, weakness and stiffness in the legs, muscle spasms, and
CC       dragging the toes when walking. In some forms of the disorder, bladder
CC       symptoms (such as incontinence) may appear, or the weakness and
CC       stiffness may spread to other parts of the body. SPG7 is a complex
CC       form. Additional clinical features are cerebellar syndrome,
CC       supranuclear palsy, and cognitive impairment, particularly disturbance
CC       of attention and executive functions. {ECO:0000269|PubMed:16534102,
CC       ECO:0000269|PubMed:17646629, ECO:0000269|PubMed:20186691,
CC       ECO:0000269|PubMed:27217339, ECO:0000269|PubMed:9635427}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Note=Defects in SPG7 may cause autosomal recessive
CC       osteogenesis imperfecta (OI). Osteogenesis imperfecta defines a group
CC       of connective tissue disorders characterized by bone fragility and low
CC       bone mass. Clinical features of SPG7-related osteogenesis imperfecta
CC       include recurrent fractures, mild bone deformities, delayed tooth
CC       eruption, normal hearing and white sclera.
CC       {ECO:0000269|PubMed:20579626}.
CC   -!- SIMILARITY: In the N-terminal section; belongs to the AAA ATPase
CC       family. {ECO:0000305}.
CC   -!- SIMILARITY: In the C-terminal section; belongs to the peptidase M41
CC       family. {ECO:0000305}.
CC   -!- CAUTION: A CDS in the 3'-UTR of SPG7 mRNA had been erroneously
CC       identified as a cell matrix adhesion regulator and originally thought
CC       to be encoded by the CMAR gene. There is no experimental evidence for
CC       the production of endogenous CMAR protein. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH35929.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BC007692; Type=Erroneous termination; Note=Truncated C-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y16610; CAA76314.1; -; mRNA.
DR   EMBL; AF080525; AAD28099.1; -; Genomic_DNA.
DR   EMBL; AF080511; AAD28099.1; JOINED; Genomic_DNA.
DR   EMBL; AF080512; AAD28099.1; JOINED; Genomic_DNA.
DR   EMBL; AF080513; AAD28099.1; JOINED; Genomic_DNA.
DR   EMBL; AF080514; AAD28099.1; JOINED; Genomic_DNA.
DR   EMBL; AF080515; AAD28099.1; JOINED; Genomic_DNA.
DR   EMBL; AF080516; AAD28099.1; JOINED; Genomic_DNA.
DR   EMBL; AF080517; AAD28099.1; JOINED; Genomic_DNA.
DR   EMBL; AF080518; AAD28099.1; JOINED; Genomic_DNA.
DR   EMBL; AF080519; AAD28099.1; JOINED; Genomic_DNA.
DR   EMBL; AF080520; AAD28099.1; JOINED; Genomic_DNA.
DR   EMBL; AF080521; AAD28099.1; JOINED; Genomic_DNA.
DR   EMBL; AF080522; AAD28099.1; JOINED; Genomic_DNA.
DR   EMBL; AF080523; AAD28099.1; JOINED; Genomic_DNA.
DR   EMBL; AF080524; AAD28099.1; JOINED; Genomic_DNA.
DR   EMBL; BC007692; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; BC035929; AAH35929.1; ALT_INIT; mRNA.
DR   EMBL; BC036104; AAH36104.1; -; mRNA.
DR   EMBL; BC110530; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; BC110531; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS10977.1; -. [Q9UQ90-1]
DR   CCDS; CCDS10978.1; -. [Q9UQ90-2]
DR   RefSeq; NP_003110.1; NM_003119.4. [Q9UQ90-1]
DR   RefSeq; NP_955399.1; NM_199367.3. [Q9UQ90-2]
DR   PDB; 2QZ4; X-ray; 2.22 A; A=305-565.
DR   PDBsum; 2QZ4; -.
DR   AlphaFoldDB; Q9UQ90; -.
DR   SMR; Q9UQ90; -.
DR   BioGRID; 112565; 154.
DR   ComplexPortal; CPX-10319; m-AAA protease complex, AFG3L2-SPG7 variant.
DR   CORUM; Q9UQ90; -.
DR   FunCoup; Q9UQ90; 1570.
DR   IntAct; Q9UQ90; 120.
DR   MINT; Q9UQ90; -.
DR   STRING; 9606.ENSP00000495795; -.
DR   MEROPS; M41.006; -.
DR   GlyGen; Q9UQ90; 2 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9UQ90; -.
DR   PhosphoSitePlus; Q9UQ90; -.
DR   BioMuta; SPG7; -.
DR   DMDM; 116242796; -.
DR   jPOST; Q9UQ90; -.
DR   MassIVE; Q9UQ90; -.
DR   PaxDb; 9606-ENSP00000268704; -.
DR   PeptideAtlas; Q9UQ90; -.
DR   ProteomicsDB; 85528; -. [Q9UQ90-1]
DR   ProteomicsDB; 85529; -. [Q9UQ90-2]
DR   Pumba; Q9UQ90; -.
DR   Antibodypedia; 30863; 415 antibodies from 21 providers.
DR   DNASU; 6687; -.
DR   Ensembl; ENST00000341316.6; ENSP00000341157.2; ENSG00000197912.17. [Q9UQ90-2]
DR   Ensembl; ENST00000645818.2; ENSP00000495795.2; ENSG00000197912.17. [Q9UQ90-1]
DR   Ensembl; ENST00000646263.1; ENSP00000494119.1; ENSG00000197912.17. [Q9UQ90-2]
DR   GeneID; 6687; -.
DR   KEGG; hsa:6687; -.
DR   MANE-Select; ENST00000645818.2; ENSP00000495795.2; NM_003119.4; NP_003110.1.
DR   UCSC; uc002fni.4; human. [Q9UQ90-1]
DR   AGR; HGNC:11237; -.
DR   ClinPGx; PA36067; -.
DR   CTD; 6687; -.
DR   DisGeNET; 6687; -.
DR   GeneCards; SPG7; -.
DR   GeneReviews; SPG7; -.
DR   HGNC; HGNC:11237; SPG7.
DR   HPA; ENSG00000197912; Low tissue specificity.
DR   MalaCards; SPG7; -.
DR   MIM; 602783; gene.
DR   MIM; 607259; phenotype.
DR   OpenTargets; ENSG00000197912; -.
DR   Orphanet; 35689; Primary lateral sclerosis.
DR   Orphanet; 99013; Spastic paraplegia type 7.
DR   VEuPathDB; HostDB:ENSG00000197912; -.
DR   eggNOG; KOG0731; Eukaryota.
DR   GeneTree; ENSGT00940000156329; -.
DR   HOGENOM; CLU_000688_23_2_1; -.
DR   InParanoid; Q9UQ90; -.
DR   OMA; RMKSMKS; -.
DR   OrthoDB; 1413014at2759; -.
DR   PAN-GO; Q9UQ90; 3 GO annotations based on evolutionary models.
DR   PhylomeDB; Q9UQ90; -.
DR   BRENDA; 3.4.24.B18; 2681.
DR   PathwayCommons; Q9UQ90; -.
DR   Reactome; R-HSA-8949664; Processing of SMDT1.
DR   Reactome; R-HSA-9837999; Mitochondrial protein degradation.
DR   SignaLink; Q9UQ90; -.
DR   Agora; ENSG00000197912; Agora Nominated Target for Alzheimer's Disease.
DR   BioGRID-ORCS; 6687; 11 hits in 1157 CRISPR screens.
DR   ChiTaRS; SPG7; human.
DR   EvolutionaryTrace; Q9UQ90; -.
DR   GeneWiki; Paraplegin; -.
DR   GeneWiki; SPG7; -.
DR   GenomeRNAi; 6687; -.
DR   Pharos; Q9UQ90; Tbio.
DR   PRO; PR:Q9UQ90; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; Q9UQ90; protein.
DR   Bgee; ENSG00000197912; Expressed in primordial germ cell in gonad and 203 other cell types or tissues.
DR   ExpressionAtlas; Q9UQ90; baseline and differential.
DR   GO; GO:1904115; C:axon cytoplasm; IEA:GOC.
DR   GO; GO:0005745; C:m-AAA complex; IDA:UniProtKB.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IDA:UniProt.
DR   GO; GO:0005757; C:mitochondrial permeability transition pore complex; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; HTP:FlyBase.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:InterPro.
DR   GO; GO:0004176; F:ATP-dependent peptidase activity; IEA:InterPro.
DR   GO; GO:0004222; F:metalloendopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0008233; F:peptidase activity; TAS:ProtInc.
DR   GO; GO:0051082; F:unfolded protein binding; TAS:ProtInc.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0008089; P:anterograde axonal transport; IEA:Ensembl.
DR   GO; GO:1902686; P:mitochondrial outer membrane permeabilization involved in programmed cell death; IMP:UniProtKB.
DR   GO; GO:0034982; P:mitochondrial protein processing; IBA:GO_Central.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0006508; P:proteolysis; TAS:ProtInc.
DR   GO; GO:0110097; P:regulation of calcium import into the mitochondrion; IDA:UniProtKB.
DR   GO; GO:0046902; P:regulation of mitochondrial membrane permeability; IMP:UniProtKB.
DR   CDD; cd19501; RecA-like_FtsH; 1.
DR   FunFam; 3.40.50.300:FF:000277; ATP-dependent zinc metalloprotease FtsH; 1.
DR   FunFam; 1.10.8.60:FF:000033; paraplegin isoform X1; 1.
DR   FunFam; 1.20.58.760:FF:000004; paraplegin isoform X1; 1.
DR   FunFam; 3.40.1690.20:FF:000002; paraplegin isoform X1; 1.
DR   Gene3D; 1.10.8.60; -; 1.
DR   Gene3D; 3.40.1690.20; -; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   Gene3D; 1.20.58.760; Peptidase M41; 1.
DR   HAMAP; MF_01458; FtsH; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR041569; AAA_lid_3.
DR   InterPro; IPR050928; ATP-dep_Zn_Metalloprotease.
DR   InterPro; IPR003959; ATPase_AAA_core.
DR   InterPro; IPR005936; FtsH.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR011546; Pept_M41_FtsH_extracell.
DR   InterPro; IPR000642; Peptidase_M41.
DR   InterPro; IPR037219; Peptidase_M41-like.
DR   NCBIfam; TIGR01241; FtsH_fam; 1.
DR   PANTHER; PTHR43655; ATP-DEPENDENT PROTEASE; 1.
DR   PANTHER; PTHR43655:SF8; PARAPLEGIN; 1.
DR   Pfam; PF00004; AAA; 1.
DR   Pfam; PF17862; AAA_lid_3; 1.
DR   Pfam; PF06480; FtsH_ext; 1.
DR   Pfam; PF01434; Peptidase_M41; 1.
DR   SMART; SM00382; AAA; 1.
DR   SUPFAM; SSF140990; FtsH protease domain-like; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Disease variant;
KW   Hereditary spastic paraplegia; Hydrolase; Membrane; Metal-binding;
KW   Metalloprotease; Mitochondrion; Mitochondrion inner membrane;
KW   Neurodegeneration; Nitration; Nucleotide-binding; Osteogenesis imperfecta;
KW   Protease; Proteomics identification; Reference proteome; Transit peptide;
KW   Transmembrane; Transmembrane helix; Zinc.
FT   TRANSIT         1..43
FT                   /note="Mitochondrion"
FT                   /evidence="ECO:0000250|UniProtKB:Q3ULF4"
FT   PROPEP          44..105
FT                   /note="Removed in mature form"
FT                   /evidence="ECO:0000250|UniProtKB:Q3ULF4"
FT                   /id="PRO_0000442305"
FT   CHAIN           106..795
FT                   /note="Mitochondrial inner membrane m-AAA protease
FT                   component paraplegin"
FT                   /id="PRO_0000084675"
FT   TOPO_DOM        106..144
FT                   /note="Mitochondrial matrix"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        145..165
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        166..248
FT                   /note="Mitochondrial intermembrane"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        249..269
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        270..795
FT                   /note="Mitochondrial matrix"
FT                   /evidence="ECO:0000255"
FT   REGION          108..133
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          701..795
FT                   /note="Interaction with PPIF"
FT                   /evidence="ECO:0000269|PubMed:26387735"
FT   REGION          751..795
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        109..133
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        575
FT                   /evidence="ECO:0000250|UniProtKB:Q9WZ49"
FT   BINDING         312
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:19841671,
FT                   ECO:0007744|PDB:2QZ4"
FT   BINDING         352
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:19841671,
FT                   ECO:0007744|PDB:2QZ4"
FT   BINDING         353
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:19841671,
FT                   ECO:0007744|PDB:2QZ4"
FT   BINDING         354
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:19841671,
FT                   ECO:0007744|PDB:2QZ4"
FT   BINDING         355
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:19841671,
FT                   ECO:0007744|PDB:2QZ4"
FT   BINDING         356
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:19841671,
FT                   ECO:0007744|PDB:2QZ4"
FT   BINDING         357
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:19841671,
FT                   ECO:0007744|PDB:2QZ4"
FT   BINDING         574
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y4W6"
FT   BINDING         578
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y4W6"
FT   BINDING         650
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y4W6"
FT   MOD_RES         505
FT                   /note="3'-nitrotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3ULF4"
FT   VAR_SEQ         443..489
FT                   /note="MGTTDHVIVLASTNRADILDGALMRPGRLDRHVFIDLPTLQERREIF -> A
FT                   SLDQLPSQGTMRKLRGKTPACSCLTEPTGSRRAMEGHSLCWGCLLH (in isoform
FT                   2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_009192"
FT   VAR_SEQ         490..795
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_009193"
FT   VARIANT         2
FT                   /note="A -> T (in dbSNP:rs535030441)"
FT                   /evidence="ECO:0000269|PubMed:16534102"
FT                   /id="VAR_063603"
FT   VARIANT         82
FT                   /note="Missing (might be implicated in the hereditary
FT                   spastic paraplegia phenotype)"
FT                   /evidence="ECO:0000269|PubMed:16534102"
FT                   /id="VAR_063604"
FT   VARIANT         284
FT                   /note="F -> P (might be implicated in the hereditary
FT                   spastic paraplegia phenotype; requires 2 nucleotide
FT                   substitutions)"
FT                   /evidence="ECO:0000269|PubMed:16534102"
FT                   /id="VAR_063605"
FT   VARIANT         294
FT                   /note="R -> H (in dbSNP:rs115661328)"
FT                   /evidence="ECO:0000269|PubMed:16534102"
FT                   /id="VAR_063606"
FT   VARIANT         349
FT                   /note="G -> S (in SPG7; function impaired;
FT                   dbSNP:rs141659620)"
FT                   /evidence="ECO:0000269|PubMed:20186691"
FT                   /id="VAR_063607"
FT   VARIANT         486
FT                   /note="R -> Q (in dbSNP:rs111475461)"
FT                   /id="VAR_063608"
FT   VARIANT         503
FT                   /note="T -> A (in dbSNP:rs2292954)"
FT                   /evidence="ECO:0000269|PubMed:16534102,
FT                   ECO:0000269|PubMed:20186691"
FT                   /id="VAR_017433"
FT   VARIANT         510
FT                   /note="A -> V (in SPG7; function impaired;
FT                   dbSNP:rs61755320)"
FT                   /evidence="ECO:0000269|PubMed:16534102,
FT                   ECO:0000269|PubMed:20186691, ECO:0000269|PubMed:27217339"
FT                   /id="VAR_063609"
FT   VARIANT         545
FT                   /note="F -> L (in dbSNP:rs758338586)"
FT                   /evidence="ECO:0000269|PubMed:16534102"
FT                   /id="VAR_063610"
FT   VARIANT         581
FT                   /note="Missing (in SPG7)"
FT                   /evidence="ECO:0000269|PubMed:16534102"
FT                   /id="VAR_063611"
FT   VARIANT         583
FT                   /note="W -> C (in SPG7; function impaired;
FT                   dbSNP:rs267607085)"
FT                   /evidence="ECO:0000269|PubMed:20186691"
FT                   /id="VAR_063612"
FT   VARIANT         603
FT                   /note="A -> T (in dbSNP:rs370852816)"
FT                   /evidence="ECO:0000269|PubMed:16534102"
FT                   /id="VAR_063613"
FT   VARIANT         623
FT                   /note="F -> C (in dbSNP:rs17783943)"
FT                   /id="VAR_048117"
FT   VARIANT         635
FT                   /note="S -> L (might be implicated in the hereditary
FT                   spastic paraplegia phenotype; dbSNP:rs864622507)"
FT                   /evidence="ECO:0000269|PubMed:16534102"
FT                   /id="VAR_063614"
FT   VARIANT         645
FT                   /note="S -> T (in dbSNP:rs2099104)"
FT                   /evidence="ECO:0000269|PubMed:16534102"
FT                   /id="VAR_059086"
FT   VARIANT         650
FT                   /note="D -> H (might be implicated in the hereditary
FT                   spastic paraplegia phenotype)"
FT                   /evidence="ECO:0000269|PubMed:16534102"
FT                   /id="VAR_063615"
FT   VARIANT         688
FT                   /note="R -> Q (in dbSNP:rs12960)"
FT                   /evidence="ECO:0000269|PubMed:16534102,
FT                   ECO:0000269|PubMed:20186691"
FT                   /id="VAR_017434"
FT   VARIANT         692
FT                   /note="S -> T (in SPG7; dbSNP:rs121918357)"
FT                   /evidence="ECO:0000269|PubMed:17646629"
FT                   /id="VAR_045898"
FT   VARIANT         730
FT                   /note="N -> D (in dbSNP:rs35749032)"
FT                   /evidence="ECO:0000269|PubMed:16534102"
FT                   /id="VAR_048118"
FT   MUTAGEN         574..577
FT                   /note="HESG->GGSS: Abolished metalloprotease activity."
FT                   /evidence="ECO:0000269|PubMed:31097542"
FT   MUTAGEN         574
FT                   /note="H->G: Loss of proteolytic activity but no loss of
FT                   interaction with PPIF; when associated with G-575 and
FT                   S-577."
FT                   /evidence="ECO:0000269|PubMed:26387735"
FT   MUTAGEN         575
FT                   /note="E->G: Loss of proteolytic activity but no loss of
FT                   interaction with PPIF; when associated with G-574 and
FT                   S-577."
FT                   /evidence="ECO:0000269|PubMed:26387735"
FT   MUTAGEN         577
FT                   /note="G->S: No loss of interaction with PPIF. Loss of
FT                   proteolytic activity but no loss of interaction with PPIF;
FT                   when associated with G-574 and G-575."
FT                   /evidence="ECO:0000269|PubMed:26387735"
FT   CONFLICT        12
FT                   /note="R -> G (in Ref. 2; AAD28099)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        376
FT                   /note="P -> A (in Ref. 3; AAH36104)"
FT                   /evidence="ECO:0000305"
FT   HELIX           315..329
FT                   /evidence="ECO:0007829|PDB:2QZ4"
FT   STRAND          344..349
FT                   /evidence="ECO:0007829|PDB:2QZ4"
FT   HELIX           355..366
FT                   /evidence="ECO:0007829|PDB:2QZ4"
FT   STRAND          370..374
FT                   /evidence="ECO:0007829|PDB:2QZ4"
FT   TURN            375..378
FT                   /evidence="ECO:0007829|PDB:2QZ4"
FT   STRAND          379..382
FT                   /evidence="ECO:0007829|PDB:2QZ4"
FT   HELIX           385..399
FT                   /evidence="ECO:0007829|PDB:2QZ4"
FT   STRAND          402..408
FT                   /evidence="ECO:0007829|PDB:2QZ4"
FT   HELIX           431..441
FT                   /evidence="ECO:0007829|PDB:2QZ4"
FT   STRAND          449..456
FT                   /evidence="ECO:0007829|PDB:2QZ4"
FT   HELIX           458..462
FT                   /evidence="ECO:0007829|PDB:2QZ4"
FT   HELIX           464..466
FT                   /evidence="ECO:0007829|PDB:2QZ4"
FT   STRAND          473..476
FT                   /evidence="ECO:0007829|PDB:2QZ4"
FT   HELIX           482..495
FT                   /evidence="ECO:0007829|PDB:2QZ4"
FT   HELIX           502..511
FT                   /evidence="ECO:0007829|PDB:2QZ4"
FT   HELIX           518..529
FT                   /evidence="ECO:0007829|PDB:2QZ4"
FT   HELIX           545..557
FT                   /evidence="ECO:0007829|PDB:2QZ4"
SQ   SEQUENCE   795 AA;  88235 MW;  453D4BF8553A0632 CRC64;
     MAVLLLLLRA LRRGPGPGPR PLWGPGPAWS PGFPARPGRG RPYMASRPPG DLAEAGGRAL
     QSLQLRLLTP TFEGINGLLL KQHLVQNPVR LWQLLGGTFY FNTSRLKQKN KEKDKSKGKA
     PEEDEEERRR RERDDQMYRE RLRTLLVIAV VMSLLNALST SGGSISWNDF VHEMLAKGEV
     QRVQVVPESD VVEVYLHPGA VVFGRPRLAL MYRMQVANID KFEEKLRAAE DELNIEAKDR
     IPVSYKRTGF FGNALYSVGM TAVGLAILWY VFRLAGMTGR EGGFSAFNQL KMARFTIVDG
     KMGKGVSFKD VAGMHEAKLE VREFVDYLKS PERFLQLGAK VPKGALLLGP PGCGKTLLAK
     AVATEAQVPF LAMAGPEFVE VIGGLGAARV RSLFKEARAR APCIVYIDEI DAVGKKRSTT
     MSGFSNTEEE QTLNQLLVEM DGMGTTDHVI VLASTNRADI LDGALMRPGR LDRHVFIDLP
     TLQERREIFE QHLKSLKLTQ SSTFYSQRLA ELTPGFSGAD IANICNEAAL HAAREGHTSV
     HTLNFEYAVE RVLAGTAKKS KILSKEEQKV VAFHESGHAL VGWMLEHTEA VMKVSITPRT
     NAALGFAQML PRDQHLFTKE QLFERMCMAL GGRASEALSF NEVTSGAQDD LRKVTRIAYS
     MVKQFGMAPG IGPISFPEAQ EGLMGIGRRP FSQGLQQMMD HEARLLVAKA YRHTEKVLQD
     NLDKLQALAN ALLEKEVINY EDIEALIGPP PHGPKKMIAP QRWIDAQREK QDLGEEETEE
     TQQPPLGGEE PTWPK
//
